Bryan Garnier - 4D Pharma (DDDD) 4D PHARMA: 4D Pharma 2018 results: candidates progressing in the clinic | CORPORATE | 465p

Report

Bryan Garnier

Gary Waanders

4D PHARMA: 4D Pharma 2018 results: candidates progressing in the clinic | CORPORATE | 465p

4D PHARMA - CORPORATE | 465p
4D Pharma 2018 results: candidates progressing in the clinic

4D Pharma in brief
2018 financial highlights
Operational highlights: clinical development in multiple diseases
4D continuing to lead the way with its innovative LBPs

21/05/2019 4 EN

Underlying

4D Pharma

4D Pharma is engaged in research and development of pharmaceutical products in live biotherapeutic areas.

See profile

GB00BJL5BR07 London Stock Exchange United Kingdom

Provider

Bryan Garnier

Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.

See profile

Analysts

Gary Waanders

Other Reports on these Companies

Bryan Garnier

Coverage dropped

October 11, 2022 October 11, 2022 1 EN

UOB

China Consumer: Positive RSV recovery in August; four key areas in the consumer space bear watching.

The yoy growth of total RSV was faster in Aug 22 (5.4%) than in Jul 22 (2.7%) on the low base in Aug 21. Despite near-term consumption being largely decided by the pandemic situation, we expect better consumption in 2H22 than in 1H22. We suggest watching four key areas in the consumer space: a) further increase in concentration (eg Jonjee), b) low penetration (eg duty-free), c) easing cost pressure (eg beer), and d) strong pricing power (eg Moutai). Maintain OVERWEIGHT on China’s consumer sector.

September 19, 2022 September 19, 2022 1 EN

BusinessWire

4D pharma Announces Positive Interim Results from the Phase I/II Study of the Combination of MRx0518 and KEYTRUDA® (pembrolizumab) for the Treatment of Renal Cell Carcinoma

LEEDS, England--(BUSINESS WIRE)-- 4D pharma plc (AIM: DDDD, NASDAQ: LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, today announces that in Part B of its signal finding study of MRx0518 in combination with MSD’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) in patients with solid tumors that have progressed on a prior immune checkpoint inhibitor (ICI), the renal cell carcinoma (RCC) group has met its primary efficacy endpoint ahead of enrollment completion. The ongoing study is being conducted in...

March 23, 2022 March 23, 2022 1 EN

Fastned: H1 results, GM recovery, roll-out acceleration expected in H2

This morning, Fastned published its H1 2025 key metrics and number of operating stations. H1 sales came in at EUR54.3m (+44% YoY), implying revenue of EUR26.3m in Q2 2025 (-9% vs cons. at EUR28.9m) and pointing to an annual run-rate of at least EUR108m (vs cons. at EUR130.8m for FY25 and STFe EUR13

August 14, 2025 August 14, 2025 1 EN

Mahaut Arnaud ... (+3)

Mahaut Arnaud
Paul de Froment
Thomas Mordelle

Avantium: financing package update

Yesterday, Avantium announced it had reached a conditional agreement with ABN AMRO, ASN, ING, Invest-NL and Rabobank to extend and amend its senior debt facility agreement, representing up to EUR125.1m as of December 2024. As such, (i) the remaining EUR14.1m debt commitment would be cancelled in ex

August 13, 2025 August 13, 2025 1 EN

Damien Choplain ... (+2)

Damien Choplain
Oscar Haffen Lamm

Valneva : Strong H1 - Key Lyme vaccine catalyst ahead in Q4

Valneva delivered a solid H1 and reaffirmed its 2025 guidance. The company’s cash position, standing at €161m, is sufficient to fund operations through 2027e, providing solid financial visibility. Looking ahead, the next key catalyst is the Phase III data readout for VLA15, Valneva’s Lyme disease v

August 12, 2025 August 12, 2025 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

4D PHARMA: 4D Pharma 2018 results: candidates progressing in the clinic | CORPORATE | 465p

Coverage dropped

China Consumer: Positive RSV recovery in August; four key areas in the consumer space bear watching.

4D pharma Announces Positive Interim Results from the Phase I/II Study of the Combination of MRx0518 and KEYTRUDA® (pembrolizumab) for the Treatment of Renal Cell Carcinoma

Fastned: H1 results, GM recovery, roll-out acceleration expected in H2

Avantium: financing package update

Valneva : Strong H1 - Key Lyme vaccine catalyst ahead in Q4

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe